CALA News and Press, Calithera Biosciences Inc. From 12/05/19

SOUTH SAN FRANCISCO, Calif., Dec. 05, 2019 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced...

Written by Daniel Cohen and Scott Matusow Karuna Therapeutics (KRTX), NextCure (NXTC), and Constellation Pharmaceuticals (CNST) are but the latest examples of how the biotech sector has been heating up. All 3 of these names have seen very strong stock appreciation on earl...

SAExploration Holdings (NASDAQ: SAEX ) +183%  on $130M of new projects in Alaska, Canada and the Middle East. More news on: SAExploration Holdings, Inc., Myovant Sciences Ltd., The Medicines Company, Stocks on the move, Read more ...

Agenus (NASDAQ: AGEN ) resumed with Buy rating and $6 (36% upside) price target at B. Riley FBR. Shares up  1%  premarket. More news on: Agenus Inc., Cabaletta Bio, Inc., Geron Corporation, Healthcare stocks news, Stocks on the move, , Read more ...

Image source: The Motley Fool. Calithera Biosciences Inc   (NASDAQ: CALA) Q3 2019 Earnings Call Nov 12, 2019 , 5:00 p.m. ET Operator Continue reading

Calithera Biosciences, Inc. (CALA) Q3 2019 Earnings Conference Call November 12, 2019 5:00 PM ET Company Participants Jennifer McNealey - Vice President of Investor Relations Susan Molineaux - Founder, President & Chief Executive Officer Keith Orford - Chief Medical Officer ...

Calithera Biosciences (NASDAQ: CALA ): Q3 GAAP EPS of -$0.38 beats by $0.06 . More news on: Calithera Biosciences, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

SOUTH SAN FRANCISCO, Calif., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, announced today...

- First presentation of preclinical data for newly-announced IL4I1 immuno-oncology program - Additional data demonstrate potential of CD73 inhibitor CB-708 to combine with immuno-oncology and chemotherapy agents in solid tumors SOUTH SAN FRANCISCO, Calif., Nov. 05, 2019 (GLOBE NEWS...

SOUTH SAN FRANCISCO, Calif., Nov. 04, 2019 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today anno...